January 15, 2025
1 min watch
Save
VIDEO: Bispecific antibodies show ‘great performance’ in lymphoma
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
SAN DIEGO — In this video, Paolo Caimi, MD, a physician and clinical investigator at Cleveland Clinic, discussed research on the use of bispecific antibodies for lymphoma presented at ASH Annual Meeting and Exposition.
“For the class of bispecifics in general, they’re showing great performance in multiple settings, including [diffuse large] B-cell lymphoma, where mosunetuzumab [Lunsumio, Genentech] and [polatuzumab vedotin (Polivy, Genentech)] subcutaneous appear to be very well tolerated,” Caimi said.
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interviews
Disclosures:
Caimi reports serving on the advisory board for ADC Therapeutics, Bristol Myers Squibb, Genentech, Luminary Therapeutics, Novartis and Synthekine; receiving honoraria from AbbVie, Arvinas, Recordati and Sobi; and research funding from AbbVie, Abcon, ADC Therapeutics, Arvinas, Bristol Myers Squibb, Genentech, Genmab, Luminary Therapeutics, Profound Bio, Recordati and Synthekine.
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.